Who Paid My Doc
Charles Dunton
Gynecologic Oncology Wynnewood, PA Medical Doctor
NPI 1336119114 CMS profile 1141641
100 E Lancaster Ave, 661 Lankenau Mob East, Wynnewood, PA 19096
General payments
$308,674
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Charles Dunton of Wynnewood, PA is reported in the CMS Open Payments database as having received $308,674 across 31 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $40 | 1 | |
| 2024 | General | $14 | 1 | |
| 2023 | General | $24 | 1 | |
| 2022 | General | $99 | 1 | |
| 2021 | General | $41 | 2 | |
| 2020 | General | $125,095 | 13 | |
| 2019 | General | $183,361 | 12 |
Beside peers
- Charles Dunton
- Gynecologic Oncology median
- Middle half of Gynecologic Oncology
- National median
In program year 2025, general payments to Charles Dunton were reported at $40. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.
Show as a table
| Year | Charles Dunton | Gynecologic Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $183,361 | $287 | $113–$1,548 | $163 |
| 2020 | $125,095 | $223 | $59–$2,164 | $114 |
| 2021 | $41 | $193 | $68–$1,139 | $132 |
| 2022 | $99 | $252 | $90–$1,151 | $149 |
| 2023 | $24 | $281 | $102–$1,419 | $160 |
| 2024 | $14 | $308 | $108–$1,502 | $164 |
| 2025 | $40 | $305 | $111–$1,499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 14 billing codesPaid by Medicare
$5,932
Medicare patients
17
Services billed
30
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Heart failure | 0% | |
| Alzheimer's or dementia | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
31 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Gynecologic Oncology in Pennsylvania
Thomas Krivak
Gynecologic Oncology · Pittsburgh, PA
Mark Shahin
Gynecologic Oncology · Hershey, PA
Joshua Kesterson
Gynecologic Oncology · Newport, PA
M Thomas
Gynecologic Oncology · Allentown, PA
Alexander Olawaiye
Gynecologic Oncology · Pittsburgh, PA
John Nakayama
Gynecologic Oncology · Pittsburgh, PA
Related records
Gynecologic Oncology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Gynecologic Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.